Close Menu

NEW YORK – Seongham, South Korea-based biotech company Bridge Biotherapeutics said the US Food and Drug Administration has accepted its investigational new drug application for BBT-176, allowing the firm to start studying the drug in non-small cell lung cancer patients who have become resistant to osimertinib (AstraZeneca's Tegrisso) due to EGFR C787S mutations.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.